Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) announced that recently, Fosun Carey (Shanghai) Biotechnology Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), initiated phase II clinical trials on FKC516 injection (hereinafter referred to as “FKC516”) for recurrent or refractory B-cell non-Hodgkin lymphoma (r/RB-NHL) in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.